CSL stock: company announces global lixudebart partnership with Alentis
Published on 10/06/2026 at 21:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CSL Limited and Alentis Therapeutics announced an exclusive global partnership on October 5, 2026, to co-develop and co-promote lixudebart. The investigational therapy targets claudin-1 and is being developed for rare kidney and liver diseases, according to CSL.
Payment and profit-sharing terms
Under the agreement, CSL will make an initial payment of US$355 million to Alentis. Alentis is eligible for up to an additional US$1.2 billion in commercial milestone payments. Once commercialized, global profits would be shared 55 percent to CSL and 45 percent to Alentis, the PRNewswire release distributed by Yonhap said.
Clinical development plans
CSL will fully fund completion of the ongoing Phase 2 RENAL trial and a planned Phase 3 trial in ANCA-associated vasculitis with rapidly progressive glomerulonephritis. The companies also plan Phase 2 studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis. An interim analysis of 26 patients in the RENAL trial showed improvement in kidney function at 24 weeks, based on eGFR and proteinuria, according to the release.
